US2012148615A1PendingUtilityA1

Polypeptides from non-typeable haemophilus influenzae

54
Assignee: MASIGNANI VEGAPriority: May 14, 2004Filed: Jan 24, 2012Published: Jun 14, 2012
Est. expiryMay 14, 2024(expired)· nominal 20-yr term from priority
Inventors:Vega MasignaniBeatrice Maria Arico
A61P 37/00A61P 37/04A61P 31/04A61P 29/00A61P 27/02A61P 31/12A61P 31/00A61P 27/16A61P 31/16A61K 2039/505A61P 11/02A61P 19/02A61K 2039/53A61P 11/04C07K 14/285A61P 11/00A61P 13/00A61K 39/102A61K 39/00
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Polypeptides comprising non-typeable Haemophilus influenzae (NTHi) amino acid sequences. Over 2500 specific NTHi proteins are disclosed. The invention also provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by H. influenzae , such as otitis media.

Claims

exact text as granted — not AI-modified
1 . An isolated, immunogenic polypeptide comprising an amino acid sequence with at least 85% sequence identity to the sequence of SEQ ID NO:3834. 
     
     
         2 . The polypeptide of  claim 1 , wherein said polypeptide comprises an amino acid sequence with at least 90% sequence identity to the sequence of SEQ ID NO:3834. 
     
     
         3 . The polypeptide of  claim 1 , wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:3834. 
     
     
         4 . A composition comprising: (a) the polypeptide of  claim 1 ; and (b) a pharmaceutically acceptable carrier. 
     
     
         5 . A composition comprising: (a) the polypeptide of  claim 2 ; and (b) a pharmaceutically acceptable carrier. 
     
     
         6 . A composition comprising: (a) the polypeptide of  claim 3 ; and (b) a pharmaceutically acceptable carrier. 
     
     
         7 . The composition of  claim 4 , further comprising an adjuvant. 
     
     
         8 . The composition of  claim 5 , further comprising an adjuvant. 
     
     
         9 . The composition of  claim 6 , further comprising an adjuvant. 
     
     
         10 . A method of treating or preventing a  Haemophilus influenzae  infection in a patient, comprising administering to the patient a therapeutically effective amount of the composition of  claim 4 . 
     
     
         11 . A method of treating or preventing a  Haemophilus influenzae  infection in a patient, comprising administering to the patient a therapeutically effective amount of the composition of  claim 5 . 
     
     
         12 . A method of treating or preventing a  Haemophilus influenzae  infection in a patient, comprising administering to the patient a therapeutically effective amount of the composition of  claim 6 . 
     
     
         13 . A method of treating or preventing a  Haemophilus influenzae  infection in a patient, comprising administering to the patient a therapeutically effective amount of the composition of  claim 7 . 
     
     
         14 . A method of treating or preventing a  Haemophilus influenzae  infection in a patient, comprising administering to the patient a therapeutically effective amount of the composition of  claim 8 . 
     
     
         15 . A method of treating or preventing a  Haemophilus influenzae  infection in a patient, comprising administering to the patient a therapeutically effective amount of the composition of  claim 9 . 
     
     
         16 . The method of  claim 10 , wherein the  H. influenzae  infection is caused by a non-typeable  H. influenzae.    
     
     
         17 . The method of  claim 11 , wherein the  H. influenzae  infection is caused by a non-typeable  H. influenzae.    
     
     
         18 . The method of  claim 12 , wherein the  H. influenzae  infection is caused by a non-typeable  H. influenzae.    
     
     
         19 . The method of  claim 13 , wherein the  H. influenzae  infection is caused by a non-typeable  H. influenzae.    
     
     
         20 . The method of  claim 14 , wherein the  H. influenzae  infection is caused by a non-typeable  H. influenzae.    
     
     
         21 . The method of  claim 15 , wherein the  H. influenzae  infection is caused by a non-typeable  H. influenzae.    
     
     
         22 . A nucleic acid molecule comprising a nucleotide sequence encoding the polypeptide of  claim 1 . 
     
     
         23 . A nucleic acid molecule comprising a nucleotide sequence encoding the polypeptide of  claim 2 . 
     
     
         24 . A nucleic acid molecule comprising a nucleotide sequence encoding the polypeptide of  claim 3 . 
     
     
         25 . A recombinant vector comprising the nucleic acid molecule of  claim 22 . 
     
     
         26 . A recombinant vector comprising the nucleic acid molecule of  claim 23 . 
     
     
         27 . A recombinant vector comprising the nucleic acid molecule of  claim 24 . 
     
     
         28 . A host cell comprising the recombinant vector of  claim 25 . 
     
     
         29 . A host cell comprising the recombinant vector of  claim 26 . 
     
     
         30 . A host cell comprising the recombinant vector of  claim 27 .

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.